Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.

Lyles SE, Milner RJ, Kow K, Salute ME.

Vet Comp Oncol. 2012 Sep;10(3):223-35. doi: 10.1111/j.1476-5829.2012.00335.x. Epub 2012 May 18.

PMID:
22594682
[PubMed - indexed for MEDLINE]
2.

Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells.

Fahey CE, Milner RJ, Kow K, Bacon NJ, Salute ME.

Anticancer Drugs. 2013 Jun;24(5):519-26. doi: 10.1097/CAD.0b013e32836002ba.

PMID:
23466652
[PubMed - indexed for MEDLINE]
3.

Phosphotyrosine enrichment identifies focal adhesion kinase and other tyrosine kinases for targeting in canine hemangiosarcoma.

Marley K, Maier CS, Helfand SC.

Vet Comp Oncol. 2012 Sep;10(3):214-22. doi: 10.1111/j.1476-5829.2012.00325.x. Epub 2012 Apr 6.

PMID:
22487216
[PubMed - indexed for MEDLINE]
4.

In vitro effects of Yunnan Baiyao on canine hemangiosarcoma cell lines.

Wirth KA, Kow K, Salute ME, Bacon NJ, Milner RJ.

Vet Comp Oncol. 2014 Jun 29. doi: 10.1111/vco.12100. [Epub ahead of print]

PMID:
24976212
[PubMed - as supplied by publisher]
5.

Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.

U'Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW.

J Vet Intern Med. 2007 Jan-Feb;21(1):113-20.

PMID:
17338158
[PubMed - indexed for MEDLINE]
6.

Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.

Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ.

J Natl Cancer Inst. 2004 Jan 7;96(1):46-55.

PMID:
14709738
[PubMed - indexed for MEDLINE]
Free Article
7.

Biological and molecular characterization of a canine hemangiosarcoma-derived cell line.

Thamm DH, Dickerson EB, Akhtar N, Lewis R, Auerbach R, Helfand SC, MacEwen EG.

Res Vet Sci. 2006 Aug;81(1):76-86. Epub 2005 Oct 25.

PMID:
16256156
[PubMed - indexed for MEDLINE]
8.

The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.

Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW.

Clin Cancer Res. 2005 Feb 15;11(4):1563-71.

PMID:
15746061
[PubMed - indexed for MEDLINE]
Free Article
9.

Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells.

Lawrence J, Saba C, Gogal R Jr, Lamberth O, Vandenplas ML, Hurley DJ, Dubreuil P, Hermine O, Dobbin K, Turek M.

Vet Comp Oncol. 2012 Jun;10(2):143-54. doi: 10.1111/j.1476-5829.2011.00291.x. Epub 2011 Aug 25.

PMID:
22236016
[PubMed - indexed for MEDLINE]
10.

Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions.

Turek M, Gogal R Jr, Saba C, Vandenplas ML, Hill J, Feldhausser B, Lawrence J.

Res Vet Sci. 2014 Apr;96(2):304-7. doi: 10.1016/j.rvsc.2014.02.001. Epub 2014 Feb 11.

PMID:
24602916
[PubMed - indexed for MEDLINE]
11.

Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.

Yokoyama T, Miyazawa K, Yoshida T, Ohyashiki K.

Int J Oncol. 2005 Jan;26(1):33-40.

PMID:
15586222
[PubMed - indexed for MEDLINE]
12.

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.

Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O.

PLoS One. 2009 Sep 30;4(9):e7258. doi: 10.1371/journal.pone.0007258.

PMID:
19789626
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.

Thamm DH, Rose B, Kow K, Humbert M, Mansfield CD, Moussy A, Hermine O, Dubreuil P.

Vet J. 2012 Jan;191(1):131-4. doi: 10.1016/j.tvjl.2011.01.001. Epub 2011 Feb 17.

PMID:
21333567
[PubMed - indexed for MEDLINE]
14.

LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate.

Mencalha AL, Du Rocher B, Salles D, Binato R, Abdelhay E.

Cancer Chemother Pharmacol. 2010 May;65(6):1039-46. doi: 10.1007/s00280-009-1109-3. Epub 2009 Aug 23.

PMID:
19701750
[PubMed - indexed for MEDLINE]
15.

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G.

Clin Cancer Res. 2003 Apr;9(4):1546-56.

PMID:
12684431
[PubMed - indexed for MEDLINE]
Free Article
16.

In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.

Avramis IA, Christodoulopoulos G, Suzuki A, Laug WE, Gonzalez-Gomez I, McNamara G, Sausville EA, Avramis VI.

Cancer Chemother Pharmacol. 2002 Dec;50(6):479-89. Epub 2002 Oct 17.

PMID:
12451475
[PubMed - indexed for MEDLINE]
17.

Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.

Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.

Cancer Chemother Pharmacol. 2009 Jun;64(1):53-65. doi: 10.1007/s00280-008-0850-3. Epub 2008 Oct 19.

PMID:
18931998
[PubMed - indexed for MEDLINE]
18.

The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line.

Wolfesberger B, Tonar Z, Gerner W, Skalicky M, Heiduschka G, Egerbacher M, Thalhammer JG, Walter I.

Res Vet Sci. 2010 Feb;88(1):94-100. doi: 10.1016/j.rvsc.2009.06.009. Epub 2009 Aug 7.

PMID:
19665156
[PubMed - indexed for MEDLINE]
19.

Masitinib is safe and effective for the treatment of canine mast cell tumors.

Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil P, Moussy A, Hermine O.

J Vet Intern Med. 2008 Nov-Dec;22(6):1301-9. doi: 10.1111/j.1939-1676.2008.0190.x. Epub 2008 Sep 24. Erratum in: J Vet Intern Med. 2009 Jan-Feb;23(1):224. Oglivie, G [corrected to Ogilvie, G].

PMID:
18823406
[PubMed - indexed for MEDLINE]
20.

Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.

Sasaki T, Tanno S, Shibukawa K, Osanai S, Kawabe J, Ohsaki Y.

Int J Oncol. 2008 Sep;33(3):525-32.

PMID:
18695882
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk